[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 5, Issue 1 (Int J Mol Cell Med 2016) ::
Int J Mol Cell Med 2016, 5(1): 30-36 Back to browse issues page
A Pilot Study of CK19, CK20 and GCC mRNA in the Peripheral Blood as a Colorectal Cancer Biomarker Panel
Pouria Mohammadi1, Massoud Saidijam1, Arastoo Kaki1, Katayoon Etemadi1, Nooshin Shabab1, Reza Yadegarazari 2
1- Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
2- Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. , reza.yadegarazari@yahoo.com
Abstract:   (4794 Views)

Colorectal cancer remains one of the major cancer- related deaths despite progress in the treatment during past decades. Detection of disease at earlier stages reduces its mortality. The aim of current study was to investigate expression of Cytokeratin 19 (CK19), Cytokeratin 20 (CK20) and Guanylyl Cyclase C (GCC) mRNA in peripheral blood of non- metastatic colorectal cancer patients which may result into introducing of  an early detection test. 25 patients with colorectal cancer and 25 healthy controls were recruited. Blood was obtained from all individuals. Expression of CK19 and CK20 and GCC mRNA and 18SrRNA (as reference gene) were determined based on real- time RT-PCR on total RNA from blood. CK19, CK20 and GCC expression had been detected in 68%, 76% & 52% of patient group, respectively, which was higher than healthy group, with 8%, 32% and 0% expression, respectively (p<0.05). CK20 was over-expressed 8- fold more in patients compared to controls. Similar result was found for CK19 with 4- fold over- expression. Sensitivity and specificity of combination of markers were 88% and 68%, respectively. Current data suggest that the detection of CK20 & CK19 as relative sensitive markers may become a valuable tool for primary diagnosis of colorectal cancer in early stages. GCC could be considered as a specific tumor marker for detection of colorectal cancer. Higher expression of these markers in patients may be considered as a relative good tool for the diagnosis of disease in non- metastatic stages.

Keywords: Colorectal cancer, cytokeratin 19, cytokeratin 20, guanylyl cyclase C, biomarker
Full-Text [PDF 269 kb]   (1577 Downloads)    
Type of Study: Original Article | Subject: Biomarkers (diagnosis & treatment)
Received: 2015/11/16 | Accepted: 2016/01/25 | Published: 2016/02/29
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammadi P, Saidijam M, Kaki A, Etemadi K, Shabab N, Yadegarazari R. A Pilot Study of CK19, CK20 and GCC mRNA in the Peripheral Blood as a Colorectal Cancer Biomarker Panel. Int J Mol Cell Med. 2016; 5 (1) :30-36
URL: http://ijmcmed.org/article-1-415-en.html


Volume 5, Issue 1 (Int J Mol Cell Med 2016) Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.05 seconds with 32 queries by YEKTAWEB 4030